Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2005-01-25
2005-01-25
Salimi, Ali R. (Department: 1648)
Chemistry: molecular biology and microbiology
Vector, per se
C435S069100, C435S235100, C424S229100, C424S199100
Reexamination Certificate
active
06846670
ABSTRACT:
The present invention provides methods of expressing a nucleic acid or producing a proteinaceous composition encoded by a nucleic acid in vascular and cardiovascular cells by administration of a herpesvirus vector. The present invention provides methods of producing a therapeutic benefit in vascular and cardiovascular tissue by administration of a herpesvirus vector. In additional aspects, the invention concerns combination therapies for vascular and cardiovascular diseases comprising administration of a herpesvirus vector and treatment with at least one addition pharmacological agent or surgical procedure.
REFERENCES:
patent: 4859587 (1989-08-01), Roizman
patent: 5288641 (1994-02-01), Roizman
patent: 5328688 (1994-07-01), Roizman
patent: 5585096 (1996-12-01), Martuza et al.
patent: 5599691 (1997-02-01), Roizman
patent: 5641651 (1997-06-01), Roizman
patent: 5728379 (1998-03-01), Martuza et al.
patent: 5795713 (1998-08-01), Roizman
patent: 5824318 (1998-10-01), Mohr et al.
patent: 5837262 (1998-11-01), Golubev et al.
patent: 5846707 (1998-12-01), Roizman
patent: 5851826 (1998-12-01), Fraefel et al.
patent: 5879934 (1999-03-01), DeLuca
patent: 6071692 (2000-06-01), Roizman
patent: 6106826 (2000-08-01), Brandt et al.
patent: 6120773 (2000-09-01), Roizman
patent: WO 9804726 (1998-02-01), None
patent: WO 9842195 (1998-10-01), None
Detrait et al, Molecular Therapy, 2002, vol. 5, No. 6, pp. 723-730.*
Smith AE (The Lancet, 1999, vol. 354 suppl. 1, pp 1-4.*
Verma et al, Nature, 1997, vol. 389, pp. 239-242.*
Coffin, et al. “Gene Delivery to the Heart In Vivo and to Cardiac Myocytes and Vascular Smooth Muscle Cells In Vitro Using Herpes Virus Vectors,”Gene Therapy3:560-566 (1996).
Mesri, et al., “Expression of Vascular Endothelial Growth Factor From a Defective Herpes Simplex Virus Type 1 Amplicon Vector Induces Angiogenesis in Mice,”Circulation Research76:161-167 (1995).
Robbins et al., “Viral Vectors for Gene Therapy,”Pharmacol. Ther. 80(1):35-47 (1998).
Yeh, et al., “Advances in Adenoviral Vectors: From Genetic Engineering to Their Biology,”FASEB Journal 11(8):615-623 (1997).
International Search Report, PCT/US01/44279, Nov. 26, 2002.
Advani et al., “Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors,”Gene Ther, 5:160-165, 1998.
Alber et al., “Herpesvirus infection accelerates atherosclerosis in the apolipoprotein E-deficient mouse,”Circ, 102:779-785, 2000.
Andreansky et al., “Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors,”Can Res, 57:1502-1509, 1997.
Baumgartner et al., “Constitutive expression of ph VEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia,”Circ, 97:1114-1123, 1998.
Chambers et al., “Comparison of genetically engineered herpes simplex virus for the treatment of brain tumors in SCID mouse model of human glioma,”PNAS, 92:1411-1415, 1995.
Chandler et al., “RNA splicing specificity determined by the coordinated action of RNA recognition motifs in SR proteins,”Proc Natl Acad Sci U S A., 94(8):3596-3601, 1997.
Chou and Roizman, “Herpes simplex virus 1 gamma-1 34.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest and DNA damage,”Proc Natl Acad Sci, 91:5247-5251, 1994.
Chou et al., “Mapping of herpes simplex virus-1 neurovirulence to gamma134.5, a gene nonessential for growth in culture,”Science, 250:1262-1266, 1990.
Dollery et al., “Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointima hyperplasia in the rat model of vascular balloon injury,”Circ, 99:3199-3205, 1999.
George et al., “Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3,”Circ, 101:296-304, 2000.
Hanna et al., “Adenoviral-mediated expression of antisense RNA to basic fibroblast growth factor reduces tangential stress in arterialized vein grafts,”J Vasc Surg, 31:770-780, 2000.
Huard, Goins, Fink, “Herpes simplex virus type I vector mediated gene transfer to muscle,” Gene Ther, 2:385-392, 1995.
Isner et al., “Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease,”Circ, 91:2687-2692, 1995.
Key et al., “Infection of vascular endothelial cells with herpes simplex virus enhances tissue factor activity and reduces thrombomodulin expression,”Proc Natl Acad Sci, 87:7095-7099, 1990.
Lachmann et al., “The use of herpes simplex virus-based vectors for gene delivery to the nervous system,”Molec Med Today, 3:404-411, 1997.
Martuza et al., “Experimental therapy of human glioma by means of a genetically engineered virus mutant,”Science, 252:854-856, 1991.
Meyerson et al., “The effects of extremely low shear stress on cellular proliferation and neointimal thickening in the failing bypass graft,”J. Vasc. Surg., 34:90-97 (2001).
Mineta, Rabkin, Martuza, “Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant,”Cancer Res, 54:3963-3966, 1994.
Miyatake et al., “Inhibition of rat vascular smooth muscle cell proliferation in vitro and in vivo by recombinant replication-competent herpes simplex virus,”Stroke, 30:2431-2438, 1999.
Moawad et al., “Adenoviral-mediated gene transfer in human and animal vein grafts using clinically relevant exposure times, pressures, and viral concentrations,”Ann. Vasc. Surg., 15:367-373 (2001).
Nabel et al., “Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo,”Nature, 362:844-846, 1993.
Nicolau et al., “Liposomes as carriers for in vivo gene transfer and expression,”Methods Enzymol., 149:157-176, 1987.
Roizman, B., “The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors,”Proc. Natl. Acad. Sci., 93:11307-11312 (1996).
Rosengart et al., “Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease,”Circ, 100:468-474, 1999.
Scheinman, et al., “p53 gene transfer to the injured rat carotid artery decreases neointimal formation,”J Vasc Surg, 29:360-369, 1999.
Schneider et al., “Adventitial delivery minimizes the proinflammatory effects of adenoviral vectors,”J Vasc Surg, 29:543-550, 1999.
Schwartz and Moawad, “Gene therapy for vascular disease,”Ann Vasc Surg, 11:189-99, 1997.
Schwartz et al., “Adenoviral-mediated transfer of a constitutively active formof the retinoblastoma gene product attenuates neointimal thickening in experimental vein grafts,”J Vasc Surg, 29:874-883, 1999.
Svensson et al., “Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors,”Circ, 99:201-205, 1999.
Symes et al., “Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease,”Ann Thor Surg, 68:830-836, 1999.
Treisman, “Transient Accumulation of c-fos RNA Following Serum Stimulation Requires a Conserved 5' Element and c-fos 3' Sequences,”Cell, 42:889, 1985.
Waugh et al., “Thrombomodulin overexpression to limit neointima formation,”Circ, 102:332-337, 2000.
Roizman Bernard
Schwartz Lewis B.
Weichselbaum Ralph R.
Marshall & Gerstein & Borun LLP
Salimi Ali R.
The University of Chicago
LandOfFree
Genetically engineered herpes virus for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Genetically engineered herpes virus for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genetically engineered herpes virus for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3386996